how glp 1 medications are changing consumer behavior Interest in GLP-1s Has Outpaced Comparable Interest in Many Tech Disruptions GLP-1 Drugs and Consumer Preferences:

The NGT meeting was conducted face-to-face, with one of the coordinating committee members (CEBM) acting as the moderator

Recent studies suggest that GLP-1R may be an important link between DM and AD

Again, serendipity intervened

44,45 Using the FDA Sentinel System, Maro et al found that the incidence of NAION was not increased within 6 months of semaglutide initiation

5 Figure 3: Pharmacy claims data show that 63% of patients initiating Wegovy or Zepbound in early 2024 remained on therapy at one year, up from 40% in the 2023 cohort

Cardiovascular Benefits: Beyond weight loss, patients may experience improvements in cardiovascular risk factors, such as lower blood pressure and improved lipid profiles